Nasal Glucagon + Intramuscular Glucagon

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hypoglycemia

Conditions

Hypoglycemia, Diabetes Mellitus, Type 1

Trial Timeline

Nov 10, 2017 → Jan 13, 2018

NCT ID

NCT03339453

About Nasal Glucagon + Intramuscular Glucagon

Nasal Glucagon + Intramuscular Glucagon is a phase 1 stage product being developed by Eli Lilly for Hypoglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03339453. Target conditions include Hypoglycemia, Diabetes Mellitus, Type 1.

What happened to similar drugs?

2 of 14 similar drugs in Hypoglycemia were approved

Approved (2) Terminated (0) Active (12)

✅Sitagliptin phosphate + PlaceboMerckApproved

✅PramlintideBristol Myers SquibbApproved

🔄Nasal GlucagonEli LillyPhase 3

🔄DasiglucagonNovo NordiskPhase 3

🔄dasiglucagon + placebo + GlucaGen HypoKitZealand PharmaPhase 3

🔄Dasiglucagon + PlaceboZealand PharmaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03339453	Phase 1	Completed	Nov 10, 2017	Jan 13, 2018	Hypoglycemia
NCT01994746	Phase 3	Completed	Nov 1, 2013	Jan 1, 2015	Diabetes Mellitus, Type 1
NCT01997411	Phase 2/3	Completed	Nov 1, 2013	Jan 1, 2015	Diabetes Mellitus, Type 1

Competing Products

20 competing products in Hypoglycemia

See all competitors

Product	Company	Stage	Hype Score
MBX 1416 (INN imapextide)	MBX Biosciences	Phase 2	36
MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C)	MBX Biosciences	Phase 1	23
Nasal Glucagon	Eli Lilly	Phase 3	40
Glucagon + Insulin	Abvance Therapeutics	Phase 1	19
Nasal Glucagon 1 mg + Nasal Glucagon 2 mg + SC Glucagon + Nasal Glucagon 3 mg	Eli Lilly	Phase 2	35
Nasal Glucagon	Eli Lilly	Phase 3	40
Eplerenone + Placebo	Johnson & Johnson	Pre-clinical	26
Sitagliptin phosphate + Placebo	Merck	Approved	43
Pasireotide	Novartis	Phase 1	29
Dasiglucagon	Novo Nordisk	Phase 3	40
Glucagen + Mayne Glucagon	Pfizer	Phase 1	29
Pramlintide	Bristol Myers Squibb	Approved	43
dasiglucagon + placebo + GlucaGen HypoKit	Zealand Pharma	Phase 3	37
Dasiglucagon + Placebo	Zealand Pharma	Phase 1	26
Dasiglucagon + Dasiglucagon + Placebo	Zealand Pharma	Phase 2	24
ZP4207 + Glucagon	Zealand Pharma	Phase 1	26
ZP4207 + Placebo	Zealand Pharma	Phase 1	26
Dasiglucagon + Placebo	Zealand Pharma	Phase 3	37
dasiglucagon + GlucaGen	Zealand Pharma	Phase 3	37
Dasiglucagon + Placebo	Zealand Pharma	Phase 2	32